Francesco Scopinaro
Research Subjects
Francesco Scopinaro has a total of 861 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe De Vincentis
Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza University of Rome, 00161 Rome, Italy
50 shared publications - Orazio Schillaci
Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
48 shared publications - Alessandro Soluri
Institute of Biomedical Engineering, CNR, Rome, Italy
43 shared publications - Alberto Signore
Nuclear Medicine Unit, Department of Medical-Surgical Sciences and of Translational Medicine, Faculty of Medicine and Psychology, “Sapienza” University, 00189 Rome, Italy
26 shared publications - Rosanna Pellegrini
Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
25 shared publications R. Pani
University La Sapienza, Rome, Italy
24 shared publications
Latest Publications
- 13 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi558
endocrine and neuroendocrine tumours 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasms
Background: The role of 18F-FDG-PET to predict clinical outcome in advanced digestive neuroendocrine neoplasms (dNENs) is still unclear. The aim is to determine the ability of 18F-FDG-PET to predict DP in patients with advanced dNENs.
- 13 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27, vi558
endocrine and neuroendocrine tumours 18F-FDG-PET to predict disease progression in advanced digestive neuroendocrine neoplasms
Background: The role of 18F-FDG-PET to predict clinical outcome in advanced digestive neuroendocrine neoplasms (dNENs) is still unclear. The aim is to determine the ability of 18F-FDG-PET to predict DP in patients with advanced dNENs.
- 21 June 2016
- Published by Elsevier in World Neurosurgery
- Vol. 93, 490.e7-490.e11
18F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports
- 21 June 2016
- Published by Elsevier in World Neurosurgery
- Vol. 93, 490.e7-490.e11
18F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports
- 2 September 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (3) , 432-440
Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours
We investigated the prognostic role of 68Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing 90Y radioembolization (90Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent 68Ga-DOTANOC PET at baseline and 6 weeks after 90Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S 90Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on 68Ga-DOTANOC PET scans performed after 90Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome. Molecular response assessed with 68Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with 90Y-RE.
- 2 September 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (3) , 432-440
Molecular response assessed by 68Ga-DOTANOC and survival after 90Y microsphere therapy in patients with liver metastases from neuroendocrine tumours
We investigated the prognostic role of 68Ga-DOTANOC in patients affected by hepatic metastases from neuroendocrine tumours (NET) undergoing 90Y radioembolization (90Y-RE). A group of 15 consecutive patients with unresectable NET liver metastases underwent 68Ga-DOTANOC PET at baseline and 6 weeks after 90Y-RE. Molecular response was defined as a reduction of >50 % in the tumour-to-spleen ratio (ΔT/S). The patients were divided into two groups (responders with ΔT/S >50 % and nonresponders with ΔT/S 90Y-RE. Statistical analysis was performed to identify factors predicting overall survival (OS) and progression-free survival (PFS). A decrease in T/S ratio was seen in all patients on 68Ga-DOTANOC PET scans performed after 90Y-RE. Nine patients were classified as responders and six as nonresponders. The mean OS in all patients was 31.0 months. Responders had a significantly (p < 0.001) longer OS (mean 36.0 ± 2.5 months) and PFS (mean 29.7 ± 3.4 months) than nonresponders. In a multivariate analysis, none of the other examined variables including age, unilobar vs. bilobar locations, bilirubin levels, radiological response or the presence of extrahepatic disease significantly predicted patient outcome. Molecular response assessed with 68Ga-DOTANOC PET might be a useful predictor of survival in patients affected by NET liver metastases treated with 90Y-RE.
- 1 April 2015
- Published by Elsevier in The Surgeon
- Vol. 13 (2) , 69-72
High-resolution, handheld camera use for occult breast lesion localization plus sentinel node biopsy (SNOLL): A single-institution experience with 186 patients
- 1 April 2015
- Published by Elsevier in The Surgeon
- Vol. 13 (2) , 69-72
High-resolution, handheld camera use for occult breast lesion localization plus sentinel node biopsy (SNOLL): A single-institution experience with 186 patients
- Open Access
- 19 March 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-7
In VivoEvaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis
Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncaseating granulomas involving intrathoracic lymph nodes and lung parenchyma. Recently, the use of anti-tumor necrosis factor alpha (anti-TNFα) agents has been introduced for therapy of chronic and refractory sarcoidosis with controversial results. Infliximab (Remicade) is a chimeric monoclonal antibody (mAb) that recognizes and binds TNFα, neutralizing its biological effects. In the present study,labelled infliximab was used to study the expression of TNFαin sarcoid lesions and to evaluate its role as a predictive marker in response to therapy with Remicade.Material and Methods. A total of 10 patients with newly diagnosed sarcoidosis were enrolled together with 10 control patients affected by rheumatoid arthritis. All patients were studied by planar imaging of the chest with-infliximab at 6 h and 24 h and total body [18F]-FDG PET/CT. Regions of interest were drawn over the lungs and the right arm and target-to-background ratios were analysed for-infliximab. SUVmeanand SUVmaxwere calculated over lungs for FDG.Results and Discussion. Image analysis showed low correlation betweenT/Bratios and BAL results in patients despite positivity at [18F]-FDG PET.Conclusion. In conclusion, patients with newly diagnosed pulmonary sarcoidosis, with FDG-PET and BAL positivity, showed a negative-infliximab scintigraphy.- 19 March 2015
- Published by Wiley in BioMed Research International
- Vol. 2015, 1-7
Open AccessIn VivoEvaluation of TNF-Alpha in the Lungs of Patients Affected by Sarcoidosis
Introduction. Sarcoidosis is a multisystemic granulomatous disorder characterized by multiple noncaseating granulomas involving intrathoracic lymph nodes and lung parenchyma. Recently, the use of anti-tumor necrosis factor alpha (anti-TNFα) agents has been introduced for therapy of chronic and refractory sarcoidosis with controversial results. Infliximab (Remicade) is a chimeric monoclonal antibody (mAb) that recognizes and binds TNFα, neutralizing its biological effects. In the present study,labelled infliximab was used to study the expression of TNFαin sarcoid lesions and to evaluate its role as a predictive marker in response to therapy with Remicade.Material and Methods. A total of 10 patients with newly diagnosed sarcoidosis were enrolled together with 10 control patients affected by rheumatoid arthritis. All patients were studied by planar imaging of the chest with-infliximab at 6 h and 24 h and total body [18F]-FDG PET/CT. Regions of interest were drawn over the lungs and the right arm and target-to-background ratios were analysed for-infliximab. SUVmeanand SUVmaxwere calculated over lungs for FDG.Results and Discussion. Image analysis showed low correlation betweenT/Bratios and BAL results in patients despite positivity at [18F]-FDG PET.Conclusion. In conclusion, patients with newly diagnosed pulmonary sarcoidosis, with FDG-PET and BAL positivity, showed a negative-infliximab scintigraphy. - 7 March 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (6) , 905-915
Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI
To compare the diagnostic information obtained with 6-[18F]-fluoro-l-3,4-dihydroxyphenylalanine (F-DOPA) PET and relative cerebral blood volume (rCBV) maps in recurrent or progressive glioma.
- 7 March 2015
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 42 (6) , 905-915
Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI
To compare the diagnostic information obtained with 6-[18F]-fluoro-l-3,4-dihydroxyphenylalanine (F-DOPA) PET and relative cerebral blood volume (rCBV) maps in recurrent or progressive glioma.
- 1 January 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (1) , 59-64
Change in total lesion glycolysis and clinical outcome after 90Y radioembolization in intrahepatic cholangiocarcinoma
- 1 January 2015
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 42 (1) , 59-64
Change in total lesion glycolysis and clinical outcome after 90Y radioembolization in intrahepatic cholangiocarcinoma
- Open Access
- 20 October 2014
- Published by Brieflands in Iranian Journal of Radiology
- Vol. 11 (3) , e9057
The Importance of Standardizing Acquisition Settings and Interpretation Criteria of Radionuclide Cisternography
Keywords: Radionuclide Cisternography; Cerebrospinal Fluid Leakage; Spontaneous Intracranial Hypotension; CSF
- 20 October 2014
- Published by Brieflands in Iranian Journal of Radiology
- Vol. 11 (3) , e9057
Open AccessThe Importance of Standardizing Acquisition Settings and Interpretation Criteria of Radionuclide Cisternography
Keywords: Radionuclide Cisternography; Cerebrospinal Fluid Leakage; Spontaneous Intracranial Hypotension; CSF
- 12 September 2014
- Published by Springer Nature in Endocrine
- Vol. 49 (1) , 163-169
Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study
Thyro-gastric autoimmunity has not been previously evaluated in patients with differentiated thyroid cancer (DTC), although its long-term complications may be relevant for the management of DTC patients. We assessed the prevalence of gastric autoimmunity and autoimmune gastritis (AG) in patients with Hashimoto’s thyroiditis (HT) and concomitant DTC. Prevalence of parietal cell antibody (PCA) positivity, iron deficiency anemia (IDA), and pernicious anemia (PA) were prospectively assessed in 150 DTC patients referred for radioiodine ablation after total thyroidectomy. Patients were classified as HT (n = 31) and non-HT (n = 119) based on a combination of serological, ultrasonographic, and histological findings. Patients with PCA positivity were subsequently addressed to endoscopy for confirmation of atrophy body gastritis, required for the diagnosis of AG. For all the variables under study, a comparison between groups was made using Fisher’s exact test and appropriate parametric and non-parametric tests. PCA positivity was significantly more prevalent in HT than in non-HT patients (12.9 vs 1.6 %, p = 0.017). After Hp eradication, a reversal of PCA positivity was observed in 3/4 patients in the HT group. IDA and PA did not differ significantly between groups. In the HT group, only one patient had endoscopical confirmation of mild gastric corporal atrophy. Gastric autoimmunity shows higher prevalence in patients with DTC and concomitant HT than in patients with DTC alone; however, in most cases, PCA positivity was associated with Hp infection. Furthermore, although previous reports found up to one-third of patients with HT to have associated AG, in our cohort AG was extremely rare.
- 12 September 2014
- Published by Springer Nature in Endocrine
- Vol. 49 (1) , 163-169
Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study
Thyro-gastric autoimmunity has not been previously evaluated in patients with differentiated thyroid cancer (DTC), although its long-term complications may be relevant for the management of DTC patients. We assessed the prevalence of gastric autoimmunity and autoimmune gastritis (AG) in patients with Hashimoto’s thyroiditis (HT) and concomitant DTC. Prevalence of parietal cell antibody (PCA) positivity, iron deficiency anemia (IDA), and pernicious anemia (PA) were prospectively assessed in 150 DTC patients referred for radioiodine ablation after total thyroidectomy. Patients were classified as HT (n = 31) and non-HT (n = 119) based on a combination of serological, ultrasonographic, and histological findings. Patients with PCA positivity were subsequently addressed to endoscopy for confirmation of atrophy body gastritis, required for the diagnosis of AG. For all the variables under study, a comparison between groups was made using Fisher’s exact test and appropriate parametric and non-parametric tests. PCA positivity was significantly more prevalent in HT than in non-HT patients (12.9 vs 1.6 %, p = 0.017). After Hp eradication, a reversal of PCA positivity was observed in 3/4 patients in the HT group. IDA and PA did not differ significantly between groups. In the HT group, only one patient had endoscopical confirmation of mild gastric corporal atrophy. Gastric autoimmunity shows higher prevalence in patients with DTC and concomitant HT than in patients with DTC alone; however, in most cases, PCA positivity was associated with Hp infection. Furthermore, although previous reports found up to one-third of patients with HT to have associated AG, in our cohort AG was extremely rare.